



(51) International Patent Classification:

G01N 35/00 (2006.01) C12M 3/00 (2006.01)
G01N 35/02 (2006.01) A61B 10/00 (2006.01)
G01N 33/48 (2006.01) C12Q 1/68 (2006.01)
G01N 33/53 (2006.01) G06F 19/10 (2011.01)
G01N 33/569 (2006.01) G01N 33/15 (2006.01)

(21) International Application Number:

PCT/US2014/054424

(22) International Filing Date:

5 September 2014 (05.09.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/874,976 6 September 2013 (06.09.2013) US
61/885,462 1 October 2013 (01.10.2013) US
62/001,039 20 May 2014 (20.05.2014) US
62/001,053 21 May 2014 (21.05.2014) US
62/010,382 10 June 2014 (10.06.2014) US

(71) Applicant: THERANOS, INC. [US/US]; 1601 S. California Ave, Palo Alto, CA 94304 (US).

(72) Inventors: PATEL, Pranav; 1601 S. California Ave, Palo Alto, CA 94304 (US). TABAKMAN, Scott; 1601 S. California Ave, Palo Alto, CA 94304 (US). BELHOCINE, Kamila; 1601 S. California Ave, Palo Alto, CA 94304 (US). RICHARDSON, Aaron; 1601 S. California Ave, Palo Alto, CA 94304 (US). LEE, Josephine; 1601 S. California Ave, Palo Alto, CA 94304 (US). SIVARAMAN, Sharada; 1601 S. California Ave, Palo Alto, CA 94304 (US). MENZES, Sheena; 1601 S. California Ave, Palo Alto, CA 94304 (US). GANGAKHEDKAR, Surekha; 1601 S. California Ave, Palo Alto, CA 94304 (US). LUI,

Clarissa; 1601 S. California Ave, Palo Alto, CA 94304 (US). HOLMES, Elizabeth; 1601 S. California Ave, Palo Alto, CA 94304 (US).

(74) Agents: FOX, James et al.; 1601 S. California Ave, Palo Alto, CA 94304 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

— with international search report (Art. 21(3))

(54) Title: SYSTEMS AND METHODS FOR DETECTING INFECTIOUS DISEASES

(57) Abstract: Systems, methods, and devices for detecting infections in a clinical sample are provided. Small-volume clinical samples obtained at a point-of-service (POS) location and may be tested at the POS location for multiple markers for multiple diseases, including upper and lower respiratory diseases. Samples may be tested for cytokines, or for inflammation indicators. Dilution of samples, or levels of detection, may be determined by the condition or past history of a subject. Test results may be obtained within a short amount of time after sample placement in a testing device, or within a short amount of time after being obtained from the subject. A prescription for treatment of a detected disorder may be provided, and may be filled, at the POS location. A bill may be automatically generated for the testing, or for the prescription, may be automatically sent to an insurance provider, and payment may be automatically obtained.

